TL;DR
CJC-1295 without DAC is discussed here as a short-acting GHRH analogue, while ipamorelin acts through a growth-hormone-secretagogue receptor pathway. The proposed reason for pairing them is to stimulate growth hormone through two different signals, but the exact combination lacks a verified direct clinical study. Evidence on long-acting CJC-1295 or ipamorelin alone should not be treated as proof for the no-DAC stack. This page separates mechanistic hypotheses from controlled evidence and does not provide a protocol.
Why I looked into it
My interest in CJC-1295 came from reading about how the body regulates growth hormone across the day, particularly the pattern of natural pulses. This is a reason for reading the research, not a recommendation to use a compound. Keith O’Beirne.
What the Research Actually Says
GHRH analogues and ghrelin-receptor agonists act through different pathways involved in growth hormone release. That is a mechanistic rationale for research, not proof that a combination improves health or performance.
The human CJC-1295 studies discussed in the CJC-1295 research guide used the long-acting compound. They cannot establish the effects of products sold as CJC-1295 without DAC or of a no-DAC/ipamorelin combination. The exact combination lacks a verified direct clinical study on this page.
Why half-life and pulses matter
Modified GRF 1-29 (Mod GRF) is discussed as a short-acting GHRH analogue. Amino-acid substitutions can slow enzymatic breakdown; the absence of an albumin-binding Drug Affinity Complex distinguishes the no-DAC concept from long-acting CJC-1295. Jetté and colleagues (2005) studied albumin-binding CJC-1295 in rats, demonstrating why albumin attachment can prolong exposure. That study does not measure a no-DAC human half-life.
A roughly 30-minute active window is often attributed to Mod GRF, but the primary studies checked here do not establish that value for the exact no-DAC compound in humans. Soule and colleagues (1994) studied a different, single-substitution GHRH analogue; its clearance cannot be assigned to Mod GRF. Growth hormone release is normally pulsatile and depends on GHRH and somatostatin regulation. A shorter signal is a pharmacological rationale for studying pulses, not proof that no-DAC products preserve a normal pattern or improve clinical outcomes.
Summary
Evidence on either compound alone does not establish the efficacy or safety of a combination. A change in growth hormone is not proof of improved strength, sleep or recovery.
CJC-1295 without DAC is not an authorised medicine in Ireland. Advertising unauthorised human medicines is prohibited; supply and import are subject to legal restrictions. Check current HPRA and Revenue guidance.
Ipamorelin is not an authorised medicine in Ireland. Advertising unauthorised human medicines is prohibited; supply and import are subject to legal restrictions. Check current HPRA and Revenue guidance.
WADA 2026 prohibits GHRH analogues and ipamorelin at all times under S2.2.4.